An Introduction to Cardiovascular Disease
Cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. CVDs describe a number of conditions affecting the heart and circulation, including coronary heart disease, angina, congenital heart disease, hypertension and stroke. The huge and ever-increasing burden of CVDs on individuals and healthcare systems shows the urgent ongoing need for treatments and preventive measures.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Cardiovascular Disease Content
Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.
- Summarize the various manifestations and multiple complications of SCD
- Appraise the practical considerations for the multidisciplinary management of SCD complications
- Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice
Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve Implantation Era
Heart International. 2023;17(1):13–8 DOI: https://doi.org/10.17925/HI.2023.17.1.13
The prevalence of aortic stenosis (AS) has grown over the last few decades, as life expectancy has increased. AS is the most common valvular disease in the developed world and is found in up to 9.8% of individuals aged ≥75.1–3 The wide range of ages, and the wide variability in the general health status in the […]
Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy
Heart International. 2023;17(1):2–4 DOI: https://doi.org/10.17925/HI.2023.17.1.2
Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease affecting 1 in 500 individuals worldwide.1 The disease pathogenesis of HCM is characterized by hypertrophy and myocyte disarray, along with muscle fibrosis on histopathology and intramural hyperplasia of the coronary arteries.2 HCM is diagnosed in patients with left ventricular hypertrophy having a maximum left ventricular wall thickness ≥15 mm […]
Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
Heart International. 2023;17(1):27–35 DOI: https://doi.org/10.17925/HI.2023.17.1.27
The systemic amyloidoses are a group of heterogenous diseases, which are characterized by the deposition of insoluble amyloid fibrils within the extracellular matrix of multiple organs throughout the body. Amyloid fibrils are formed from the misfolding of amyloid precursor proteins (APPs) into insoluble, beta-pleated sheets that are resistant to proteolysis. They are histologically characterized by […]
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Steven Nissen, ACC 2023: CLEAR OUTCOMES trial – Bempedoic acid and cardiovascular outcomes in statin intolerant patients
CLEAR OUTCOMES trial investigated bempedoic acid and cardiovascular outcomes in statin intolerant patients with high cardiovascular risk. Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) addresses the findings, and what the implications are for clinical practice and patient care in this touchCARDIO interview. Prof. Nissen also discusses the use of statins as the cornerstone to […]
Transcatheter Mitral Valve Replacement in Patients with Mitral Annular Calcification: A Review
Heart International. 2023;17(1):19–26 DOI: https://doi.org/10.17925/HI.2023.17.1.19
Mitral valve (MV) disease includes either mitral regurgitation or mitral stenosis or both. The incidence and prevalence of valvular heart disease is increasing with the increasing population age. Degenerative MV disease poses a global burden with a prevalence of 18.1 million cases in 2017. Further, its global prevalence increased by 94% from 1990 to 2017.1 Surgery is the gold standard of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!